Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07816341Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of F182112 in autoimmune hemolytic anemia (AIHA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence of adverse events at 28 days. Started Oct 2026; status: recruiting.
02
Drugs
F182112
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07816341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816341.